Living with late stage prostate cancer

There is a valuable video interview that was put on line a couple of days ago featuring Dr. William Oh of the Mount Sinai Hospital and Medical School in New York and Jan Manarite of the Prostate Cancer Research Institute. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …

Another kinase inhibitor shows only “modest” activity in men with mCRPC

A relatively small Phase II trial, carried out in France and Germany, has suggested that a new kinase inhibitor called nintedanib has only “modest” activity in the treatment of post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Sweeney et al. present results of CHAARTED trial at ASCO

So the data from the CHAARTED trial will be presented this afternoon at the ASCO meeting. This is the one really major and positive study result related to prostate cancer that we knew was coming at this meeting. … READ MORE …

Sunday morning’s news from the ASCO annual meeting

We commented earlier on several of the prostate cancer presentations given this morning at the American Society for Clinical Oncology (ASCO) meeting — see here and here. However, there was another important paper presented this morning. … READ MORE …

What’s being presented at ASCO this year: I

So here are some links to some initial key papers to be presented at ASCO this year. These four papers all address important issues affecting the treatment of metastatic and later stages of prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers